Evolocumab

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1066 publications

Early PCSK9 Inhibitor Use Correlates With Improved Outcomes in Patients With Acute Stroke Receiving Endovascular Therapy.

Early PCSK9 Inhibitor Use Correlates With Improved Outcomes in Patients With Acute Stroke Receiving Endovascular Therapy.

Journal: Journal of the American Heart Association

Published: April 07, 2026

Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Research Summary.

Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Research Summary.

Journal: JAMA

Published: March 28, 2026

Pharmacological management of elevated LDL in patients with hypercholesterolaemia and mixed dyslipidaemia.

Pharmacological management of elevated LDL in patients with hypercholesterolaemia and mixed dyslipidaemia.

Journal: Expert opinion on pharmacotherapy

Published: March 05, 2026

In adults at high CV risk and without previous MI or stroke, evolocumab reduced major adverse CV event composites at a median 4.6 y.

In adults at high CV risk and without previous MI or stroke, evolocumab reduced major adverse CV event composites at a median 4.6 y.

Journal: Annals of internal medicine

Published: March 02, 2026

Evaluation of evolocumab on saphenous vein graft patency following coronary artery bypass graft surgery in people living with and without diabetes in the NEWTON-CABG CardioLink-5 trial.

Evaluation of evolocumab on saphenous vein graft patency following coronary artery bypass graft surgery in people living with and without diabetes in the NEWTON-CABG CardioLink-5 trial.

Journal: Diabetes, obesity & metabolism

Published: February 01, 2026

Novel Approaches to Lipid Management: Beyond Statins and PCSK9 Inhibitors.

Novel Approaches to Lipid Management: Beyond Statins and PCSK9 Inhibitors.

Journal: Journal of clinical medicine research

Published: January 30, 2026

PCSK9 Inhibitors in Peripheral Arterial Disease: A Systematic Review.

PCSK9 Inhibitors in Peripheral Arterial Disease: A Systematic Review.

Journal: Annals of vascular surgery

Published: January 20, 2026

Effect of evolocumab on the gut microbiota in patients with acute myocardial infarction.

Effect of evolocumab on the gut microbiota in patients with acute myocardial infarction.

Journal: Journal of medical microbiology

Published: January 13, 2026

Correction.

Correction.

Journal: The Medical letter on drugs and therapeutics

Published: January 08, 2026

Real-world effectiveness and cardiovascular outcomes of PCSK9 inhibitor therapy: a prospective registry study.

Real-world effectiveness and cardiovascular outcomes of PCSK9 inhibitor therapy: a prospective registry study.

Journal: Lipids in health and disease

Published: January 07, 2026

The possible role of PCSK9 inhibitors in cardiac syndrome X: Bridging microvascular dysfunction, endothelial pathobiology, and molecular pharmacotherapy.

The possible role of PCSK9 inhibitors in cardiac syndrome X: Bridging microvascular dysfunction, endothelial pathobiology, and molecular pharmacotherapy.

Journal: Microvascular research

Published: December 31, 2025

Relationship Between Achieved LDL-C and Saphenous Vein Graft Patency: A Post Hoc Analysis of the NEWTON-CABG CardioLink-5 Study.

Relationship Between Achieved LDL-C and Saphenous Vein Graft Patency: A Post Hoc Analysis of the NEWTON-CABG CardioLink-5 Study.

Journal: European journal of preventive cardiology

Published: December 20, 2025

Showing 1-12 of 1,066

Last Updated: 04/28/2026